Biocept, Inc. (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

BIOC has been the topic of a number of other reports. ValuEngine downgraded Biocept from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 8th. Westpark Capital reaffirmed an “outperform” rating on shares of Biocept in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $2.31.

Biocept (NASDAQ:BIOC) traded down 5.200% on Wednesday, hitting $1.185. The company had a trading volume of 411,477 shares. The company’s market capitalization is $31.52 million. The stock’s 50-day moving average price is $1.39 and its 200 day moving average price is $1.68. Biocept has a one year low of $0.74 and a one year high of $3.39.

Biocept (NASDAQ:BIOC) last posted its quarterly earnings results on Thursday, August 10th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.01. Biocept had a negative return on equity of 878.16% and a negative net margin of 359.48%. The firm had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.23 million. On average, analysts expect that Biocept will post $0.40 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Biocept by 9.6% in the second quarter. Vanguard Group Inc. now owns 764,351 shares of the medical research company’s stock valued at $1,048,000 after buying an additional 66,746 shares during the period. Creative Planning increased its stake in shares of Biocept by 64,679.8% in the second quarter. Creative Planning now owns 246,811 shares of the medical research company’s stock valued at $338,000 after buying an additional 246,430 shares during the period. WealthTrust Axiom LLC bought a new stake in shares of Biocept during the first quarter valued at approximately $298,000. Finally, Intellectus Partners LLC increased its stake in shares of Biocept by 6,250.0% in the first quarter. Intellectus Partners LLC now owns 127,000 shares of the medical research company’s stock valued at $271,000 after buying an additional 125,000 shares during the period. 15.27% of the stock is owned by hedge funds and other institutional investors.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with's FREE daily email newsletter.